4475 EXECUTIVE DRIVE, SAN DIEGO, CA
Reports Second Quarter 2026 Financial Results and Recent Business Highlights
News, Articles of Incorporation
Calidi Biotherapeutics Enters New Lease Agreement Saving $1.1 Million Annually
Appoints Former Executive Corsee Sanders, Ph.D., to Board of Directors
Election of Scott Leftwich as Class III Director at Annual Meeting
News, Securities Holder Rights or Indentures
Reports First Quarter 2026 Financial Results and Recent Operational Highlights
Calidi Biotherapeutics Issues Warrant for 17.39M Shares at $0.23
Q2
Q1
FY 2025
Q3
FY 2024
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Additional Securities
Prospectus filed pursuant to Rule 424(b)(4)
Effectiveness Notice
S-1
Registration Statement for Securities Offered under a Shelf Registration
Additional Proxy Materials
PRE 14A
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Correspondence
Submission Upload